ATMI Introduces Ready-to-Use, Sterile Pyrofree Vials
ATMI, Inc., a global technology company and leader in single-use bioprocess solutions, has introduced a line of pyrogen-free vials in collaboration with Disposable Lab (D-Lab), a Bordeaux, France-based contract-manufacturing company. Designed to meet biopharmaceutical filling and final packaging needs, the patent-pending Pyrofree vials are the only cost-effective, ready-to-use vials guaranteed to be both pyrogen-free and sterile upon delivery.
"We have come together with D-Lab to offer this comprehensive solution in support of our customers' end goal of advancing patient health and safety," said Senior Vice President and General Manager of ATMI LifeSciences, Mario Philips. "Pyrofree vials can be incorporated into ATMI's existing ultra-clean sterile packaging and fill/finish technologies, or used independently."
Pyrogens are a substance that induce rapid onset of fever with the potential to cause sepsis or progressive septic shock if they enter a patient's bloodstream. This makes it critical to ensure that pyrogens are not present in biopharmaceutical products. While difficult, the most common techniques to remove pyrogens are either inactivation or destruction of the molecule through depyrogenation.
ATMI subjects all Pyrofree vials to a thorough depyrogenation process that includes washing (with water for injection) and heating the vials to high temperatures in a polyether ether ketone (PEEK) bag to achieve a three-log reduction. Process specifications can be further modified based on customer requests.
"Pyrofree brings several clear benefits including the most cost-effective solution on the market, scalability from small to commercial-scale batches, and availability in both molded and tubular formats," noted Jean-Pascal Zambaux, inventor of Pyrofree and majority owner of D-Lab. "The vials may also be used for commercial safety stocks of injectables, and feature sizes up to 1 liter."
Pyrofree vials are made to withstand the high temperatures during depyrogenation and sterilization. After these steps, the vials are double-vacuum-packed in a PEEK bag for tamper-evidence, as well as to maintain sterility and guarantee no external contact. A third PE/PA film layer is added to the packaging under vacuum in a Class C cleanroom to protect the vials from any breakage during transportation and eliminate the need for a support tray.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance